Display options
Cite
Luo J, Chen B, Ji XX, et al. Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3. Tumour Biol. 2015;doi: 10.1007/s13277-015-3850-z.
Luo, J., Chen, B., Ji, X. X., Zhou, S. W., & Zheng, D. (2015). Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, . https://doi.org/10.1007/s13277-015-3850-z
Luo, Jie, et al. "Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3." Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine vol. (2015). doi: https://doi.org/10.1007/s13277-015-3850-z
Luo J, Chen B, Ji XX, Zhou SW, Zheng D. Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3. Tumour Biol. 2015 Aug 28; doi: 10.1007/s13277-015-3850-z. Epub 2015 Aug 28. PMID: 26314855.
Copy Download .nbib Format: NLM
Share it on

Tumour Biol. 2015 Aug 28; doi: 10.1007/s13277-015-3850-z. Epub 2015 Aug 28.

Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Jie Luo, Bin Chen, Xian-Xiu Ji, Song-Wen Zhou, Di Zheng

Affiliations

  1. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, 507 Zhengmin Road, Shanghai, 200433, China.

PMID: 26314855 DOI: 10.1007/s13277-015-3850-z

Abstract

Nonsmall cell lung cancer (NSCLC) is a commonly occurring lung cancer. A combination of molecular biological treatments with regular chemotherapy may result in improved therapeutic outcome. Here, we reported significantly higher levels of fibroblast growth factor receptor 3 (FGFR3) and significantly lower levels of miR-100 in the NSCLC specimen, compared to the paired NSCLC-adjacent normal lung tissues. Moreover, the levels of FGFR3 and miR-100 were inversely correlated. Bioinformatics analyses followed by luciferase reporter assay showed that miR-100 bound to the 3'-UTR of FGFR3 messenger RNA (mRNA) to inhibit its translation. Overexpression of miR-100 in NSCLC cells decreased FGFR3 protein levels, whereas inhibition of miR-100 increased FGFR3 protein levels, without affecting FGFR3 mRNA levels. Furthermore, overexpression of miR-100 suppressed cancer growth, migration, and chemosensitivity in NSCLC cells, while inhibition of miR-100 significantly facilitated them. Taken together, our data demonstrate that miR-100 may inhibit NSCLC through FGFR3.

References

  1. Eur J Cancer. 2014 May;50(8):1541-54 - PubMed
  2. Mol Ther. 2013 May;21(5):986-94 - PubMed
  3. Cell. 2012 Sep 14;150(6):1107-20 - PubMed
  4. Cancer Res. 2010 May 1;70(9):3606-17 - PubMed
  5. Tumour Biol. 2014 Dec;35(12):11751-9 - PubMed
  6. Exp Ther Med. 2012 Jan;3(1):149-153 - PubMed
  7. J Neurosci. 2010 May 12;30(19):6595-606 - PubMed
  8. Int J Oncol. 2013 Aug;43(2):548-60 - PubMed
  9. Cell Physiol Biochem. 2015;35(3):1137-50 - PubMed
  10. Hepatology. 2015 Dec;62(6):1767-78 - PubMed
  11. Cell Physiol Biochem. 2014;33(4):953-66 - PubMed
  12. Cell Physiol Biochem. 2015;35(5):1677-88 - PubMed
  13. Cell Physiol Biochem. 2014;34(6):1863-76 - PubMed
  14. Cell Physiol Biochem. 2014;33(2):289-99 - PubMed
  15. Tumour Biol. 2014 Jul;35(7):6673-8 - PubMed
  16. Mol Ther. 2014 Aug;22(8):1494-1503 - PubMed
  17. Cancer Res. 2013 Sep 15;73(18):5730-41 - PubMed
  18. Differentiation. 2007 Sep;75(7):638-51 - PubMed
  19. J Natl Cancer Inst. 1973 Nov;51(5):1417-23 - PubMed
  20. Cell Physiol Biochem. 2014;34(4):1166-74 - PubMed
  21. Pancreas. 2012 Nov;41(8):1280-4 - PubMed
  22. Cancer Lett. 2012 Apr 28;317(2):184-91 - PubMed
  23. Int J Biochem Cell Biol. 2004 Jul;36(7):1154-60 - PubMed
  24. Cell Physiol Biochem. 2014;33(5):1261-71 - PubMed
  25. Cell Physiol Biochem. 2015;35(3):997-1007 - PubMed
  26. Nat Protoc. 2007;2(2):329-33 - PubMed
  27. Ann Oncol. 2014 Mar;25(3):552-63 - PubMed
  28. Nucleic Acids Res. 2013 Jul;41(Web Server issue):W159-64 - PubMed
  29. Cell Physiol Biochem. 2014;34(3):865-72 - PubMed
  30. Int J Biochem Cell Biol. 2011 Jul;43(7):1030-44 - PubMed
  31. Tumour Biol. 2014 Nov;35(11):11051-6 - PubMed
  32. Biochem J. 2011 Jul 15;437(2):199-213 - PubMed
  33. Oncol Lett. 2015 Jul;10(1):543-549 - PubMed
  34. BMC Cancer. 2012 Nov 14;12:519 - PubMed
  35. Clin Cancer Res. 2012 Apr 1;18(7):1855-62 - PubMed
  36. Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):E3355-64 - PubMed
  37. Cell Physiol Biochem. 2015;35(3):899-912 - PubMed
  38. J Biol Chem. 2004 Nov 12;279(46):47912-28 - PubMed
  39. Cell Physiol Biochem. 2014;34(6):2007-16 - PubMed
  40. Cell Physiol Biochem. 2014;33(2):457-67 - PubMed
  41. Cell Signal. 2015 Jun;27(6):1208-13 - PubMed
  42. Cancer Res. 2013 Aug 15;73(16):5195-205 - PubMed

Publication Types